Market News
Smart Trading. Simplified.
Tired of losing money in volatile markets?
Enter the "Vomma Zone." A unique market environment discovered by former TD Ameritrade educator Don Kaufman that makes massive profits available to every trader.
Don has a special member-only video briefing that teaches traders how to thrive in extreme volatility.
Learn the ins, outs, tricks, and tips expert traders use daily to spot this unique moment in the market.
5 Stocks with Buybacks That Are Undervalued
Barrick Gold Corporation (GOLD) Warren Buffett made waves recently after it was reported his Berkshire Hathaway investment fund sold its entire $564 million stake in Barrick Gold earlier this year. But the famed Oracle of Omaha might have been a little too quick on the draw, as the mining firm just posted one of its […]
The World's First $2 Trillion Drug?
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
John Donahoe Leadership Style
As the CEO of Nike Inc (NYSE:NKE) John Donahoe is the head of one of the largest and most recognizable brands in the world. The company is the most valuable global apparel brand, valued at over $210 billion. It navigated the past year expertly through its strong digital infrastructure, but it wasn’t easy. The current […]
Tiny Biotech Creates $2 Trillion Drug
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Will Lululemon Stock Go Up?
Will Lululemon Benefit From Reopening Boom? A recent Jefferies consumer spending survey found that 23% of US participants named clothing and accessories as their main priority purchase preference once the pandemic-hit economy fully opens again, second only to restaurants and bars. As a consequence of increased spending, analysts expect apparel stocks to thrive, as more and […]
"The Biggest Drug Ever"
On August 23, 2018, a small biotech won a patent for a treatment that could help as many as 50 million people and save the U.S. as much as $20 TRILLION. Jim Cramer says a drug like this would be "The Biggest Drug Ever."
Our research shows that anyone who gets in today could turn every $1,000 into $1.1 million >>>
3 Cryptos That Beat Bitcoin
Cryptos That Beat Bitcoin: Without fail, cryptocurrency has managed to dominate a vast majority of the conversation among retail investors and traders for much of 2021. From Bitcoin to Dogecoin, investors of all shapes and sizes are desperate to find the cryptocurrency that will increase rapidly and exponentially to make the most of their investments. […]
Unique market conditions lead to massive potential...
Intense volatility...
FOMO...
Unprecedented current events...
...all these lead to a unique market climate where MASSIVE profits become possible.
But not without the correct playbook... the playbook used by professional traders around the globe.
Join the former TD Ameritrade educator as he breaks down the exact strategies he uses when the market enters what he calls a "VOMMA ZONE."
How High Will Shopify Stock Go?
How High Will Shopify Stock Go? Shopify Inc (NYSE:SHOP) had a banner year in 2020, growing from a low of around $350 to well over $1,000 per share. At a time when a lot of businesses were forced to go online to survive, ecommerce platforms with a pre-built infrastructure like Shopify were favored. There are […]
FREE Investing eBook - 3 Reasons Why Investors Flock to Real Estate Stocks
Get the new eBook from Millionacres, the leaders in real estate investment advice. The eBook details the key reasons why savvy investors look to real estate stocks during volatile markets...like now!
For Safe Haven or Growth, these stocks can help investors weather a storm.
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment